Zai Lab Ltd (1ZLB) AI Stock Analysis

2 Followers

Zai Lab Ltd

(Frankfurt:1ZLB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified biotech platformZai Lab has exposure to several therapeutic areas and combines in-licensed assets with internally developed candidates and commercial medicines. This diversified model can spread development risk, support multiple growth avenues, and sustain a broader long-term opportunity set.

Negative Factors

Persistent unprofitabilityZai Lab remains materially unprofitable despite a healthy gross margin and improvement from earlier losses. Continued operating and net losses limit internally funded expansion, require sustained investment to reach scale, and leave the company without a demonstrated path to consistent break-even.

Zai Lab Ltd (1ZLB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.96B
Dividend Yield: ―
Average Volume (3M): 2,990
Price to Earnings (P/E): -14.3
Beta (1Y): 0.89
Revenue Growth: -4.89%
EPS Growth: 14.16%
Country: Germany
Employees: 1,784
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Zai Lab Ltd Business Overview & Revenue Model

Company Description

Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, a...

Zai Lab Ltd Risk Analysis

Zai Lab Ltd disclosed 101 risk factors in its most recent earnings report. Zai Lab Ltd reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We may experience operational, regulatory, and competitive risks due to our use of artificial intelligence.Q4, 2025

2.Because of volatility in the price of our securities and the share price of biotechnology and biopharmaceuticals companies more broadly, we may be at increased risk of securities class action litigation.Q4, 2023

3.We and our subsidiaries have entered into debt arrangements with certain financial institutions in China, and we may in the future consider additional debt arrangements, to fund our business or working capital needs. Such debt arrangements may restrict our future operations.Q4, 2023

Zai Lab Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1ZLB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:9969	65Neutral	HKD 17.35B	12.83	17.47%	―	146.27%	―
HK:1952	64Neutral	HKD 9.06B	-137.37	-1.02%	―	192.64%	92.31%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:6855	50Neutral	HKD 10.45B	-6.14	-153.78%	―	70.26%	-12.79%
HK:2616	47Neutral	HKD 8.19B	-16.38	-43.54%	―	116.67%	-0.42%
HK:2171	39Underperform	HKD 6.20B	-55.28	-9.45%	―	68.12%	81.84%

* Healthcare Sector Average

Performance Comparison

DE:1ZLB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1ZLB	Zai Lab Ltd	2.28	0.45	24.66%
HK:9969	InnoCare Pharma Ltd.	11.61	-3.18	-21.50%
HK:1952	Everest Medicines Ltd.	25.54	-21.00	-45.12%
HK:2171	CARsgen Therapeutics Holdings Ltd.	10.44	-7.04	-40.27%
HK:2616	CStone Pharmaceuticals	5.21	-0.54	-9.48%
HK:6855	Ascentage Pharma Group International	28.10	-37.15	-56.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Zai Lab Ltd AI Stock Analysis